GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tyra Biosciences Inc (NAS:TYRA) » Definitions » 5-Year RORE %

TYRA (Tyra Biosciences) 5-Year RORE % : 0.00% (As of Sep. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Tyra Biosciences 5-Year RORE %?

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. Tyra Biosciences does not have enough data to calculate 5-Year RORE %.


Tyra Biosciences 5-Year RORE % Historical Data

The historical data trend for Tyra Biosciences's 5-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tyra Biosciences 5-Year RORE % Chart

Tyra Biosciences Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
5-Year RORE %
- - - - -

Tyra Biosciences Quarterly Data
Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
5-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Tyra Biosciences's 5-Year RORE %

For the Biotechnology subindustry, Tyra Biosciences's 5-Year RORE %, along with its competitors' market caps and 5-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tyra Biosciences's 5-Year RORE % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tyra Biosciences's 5-Year RORE % distribution charts can be found below:

* The bar in red indicates where Tyra Biosciences's 5-Year RORE % falls into.



Tyra Biosciences 5-Year RORE % Calculation

Tyra Biosciences's 5-Year RORE % for the quarter that ended in Sep. 2024 is calculated as:

5-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 5-year -Cumulative Dividends per Share for 5-year )
=( - )/( - )
=/
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 5-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Sep. 2024 and 5-year before.


Tyra Biosciences  (NAS:TYRA) 5-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 5-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


Tyra Biosciences 5-Year RORE % Related Terms

Thank you for viewing the detailed overview of Tyra Biosciences's 5-Year RORE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Tyra Biosciences Business Description

Traded in Other Exchanges
N/A
Address
2656 State Street, Carlsbad, CA, USA, 92008
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology The Company's in-house precision medicine platform, SNÅP, enables rapid and precise drug design through iterative molecular SNAPshots that help predict genetic alterations most likely to cause acquired resistance to existing therapies. Its lead product candidate is TYRA 300, an FGFR3 selective inhibitor with an initial focus on patients with metastatic urothelial carcinoma of the bladder and urinary tract (mUC).
Executives
Nina S Kjellson director C/O INTERWEST PARTNERS, 2710 SAND HILL ROAD, SUITE 200, MENLO PARK CA 94025
Ra Capital Healthcare Fund Lp director, 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Alan Fuhrman officer: Chief Financial Officer C/O AMBIT BIOSCIENCES CORPORATION, 11080 ROSELLE STREET, SAN DIEGO CA 92121
Todd Harris director, officer: Chief Executive Officer 30699 RUSSELL RANCH ROAD, SUITE 140, WESTLAKE VILLAGE CA 91362
Daniel Bensen officer: Chief Operating Officer C/O TYRA BIOSCIENCES, INC, 2656 STATE STREET, CARLSBAD CA 92008
Mva Investors, Llc 10 percent owner 12860 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
Aaron I. Davis 10 percent owner 12860 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
Ali D. Fawaz officer: General Counsel and Secretary C/O TYRA BIOSCIENCES, INC., 2656 STATE STREET, CARLSBAD CA 92008
John Stephen Healy officer: General Counsel and Secretary C/O TYRA BIOSCIENCES, INC., 2656 STATE STREET, CARLSBAD CA 92008
Boxer Capital, Llc 10 percent owner 12860 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
Alta Partners Nextgen Fund Ii, L.p. 10 percent owner 4 EMBARCADERO CENTER, SUITE 2100, SAN FRANCISCO CA 94111
Cormorant Asset Management, Lp 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Robert J More director, 10 percent owner 680 S CACHE STREET, SUITE 100, BOX 10820, JACKSON WY 83001
Melissa Mccracken director C/O TYRA BIOSCIENCES, INC, 2656 STATE STREET, CARLSBAD CA 92008
Siddarth Subramony director C/O TYRA BIOSCIENCES, INC, 2656 STATE STREET, CARLSBAD CA 92008